Reports Q3 revenue $0.9M vs. $1.4M last year.”The public markets are not yet reflecting the true value of ProPhase or the multi-year opportunities now in front of us,” said Ted Karkus, CEO and Chairman. “With Crown Medical recoveries underway, a validated and commercially ready cancer test with significant market potential, and a restructured, profitable genomics business, we see a clear path to value creation that we believe far exceeds our current share price.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRPH:
- ProPhase Labs urges shareholders to vote ‘FOR’ all proposed resolutions
- ProPhase Labs Delays Q3 Filing Amid Reorganization
- ProPhase Labs announces publication of BE-Smart Esophageal Cancer study
- ProPhase Labs engages RedChip to lead investor relations efforts
- ProPhase Labs announces study validating BE-Smart cancer test